A systematic pharmacological investigation of pharmacologically active ingredients in Toujie Quwen granules for treatment of COVID-19.
10.12122/j.issn.1673-4254.2020.08.02
- Author:
Shitang MA
1
;
Xue ZHANG
1
;
Jinfeng CEN
1
;
Ge HONG
2
;
Shengwei HONG
3
;
Wenzheng JU
3
Author Information
1. School of Life and Health Sciences, Anhui Science and Technology University, Fengyang 233100, China.
2. Institute of Biomedical Engineering, Peking Union Medical College, Chinese Academy of Medical Sciences, Tianjin 300192, China.
3. Nanjing University of Chinese Medicine, Nanjing 200019, China.
- Publication Type:Journal Article
- Keywords:
Toujie Quwen granules;
coronavirus disease 2019;
pharmacologically active ingredients;
systemic pharmacology
- MeSH:
Betacoronavirus;
Coronavirus Infections;
drug therapy;
Drugs, Chinese Herbal;
Humans;
Medicine, Chinese Traditional;
Pandemics;
Pneumonia, Viral;
drug therapy
- From:
Journal of Southern Medical University
2020;40(8):1072-1080
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the pharmacologically active ingredients in granules (TJQW) for treatment of coronavirus disease 2019 (COVID-19) in light of systemic pharmacology.
METHODS:We performed database search, literature mining and drug-like index screening to identify the bioactive components in TJQW, the positive drugs for disease treatment and their therapeutic targets. The core disease target was investigated based on the cross-linking interaction of the bioactive components, positive drug and potential disease target, and the target proteins at the key nodes were analyzed by GO and KEGG analyses. Based on the therapeutic targets for COVID-19, virtual screening was conducted to screen the compounds in TJQW and construct the network cross-linking the key bioactive molecules in TJQW, key node targets of the disease, and the related biological pathways.
RESULTS:We identified 159 compounds in TJQW and obtained 18 core proteins based on the cross-linking of the bioactive components, positive drugs and disease targets. The key node targets consisted of 22 targets including the latest 4 COVID-19 proteins. Virtual screening results showed that at least 14 compounds could bind with the core disease target proteins. The material basis of TJQW for COVID-19 treatment was explained in multi-pathway, multi-component and multi-target perspectives. In terms of the structural characteristics of the compounds, we screened the top 30 molecules with strong binding with the target proteins, among which flavonoids were the predominant components.
CONCLUSIONS:This investigation reveals the therapeutic mechanism of TJQW for COVID-19 involving multiple components, targets and pathways from the perspective of key bioactive molecules, disease key node targets and related biological pathways. We screened 30 active precursors from TJQW, which provides reference for the clinical application and further development of TJQW.
